Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Shares Outstanding (2016 - 2025)

CorMedix's Shares Outstanding history spans 14 years, with the latest figure at $92.0 for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 99.86% year-over-year to $92.0; the TTM value through Dec 2025 reached $92.0, down 99.86%, while the annual FY2025 figure was $92.0, 100.0% down from the prior year.
  • Shares Outstanding for Q4 2025 was $92.0 at CorMedix, down from $91623.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $74.6 million in Q2 2025 and bottomed at $92.0 in Q4 2025.
  • The 5-year median for Shares Outstanding is $181622.0 (2021), against an average of $16.4 million.
  • The largest annual shift saw Shares Outstanding plummeted 99.9% in 2021 before it surged 131107.09% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $38.1 million in 2021, then rose by 12.42% to $42.8 million in 2022, then grew by 28.02% to $54.8 million in 2023, then plummeted by 99.88% to $64411.0 in 2024, then plummeted by 99.86% to $92.0 in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Shares Outstanding are $92.0 (Q4 2025), $78.3 million (Q3 2025), and $91623.0 (Q2 2025).